Scientific Committee on Antarctic Research

Dr. Andy Pearson receives Special Plaque for nearly two decades of research paper contribution at the 10th IIR Conference on Ammonia and CO2 Refrigeration Technologies

Retrieved on: 
Saturday, June 10, 2023
Faculty, International Institute of Refrigeration, IIR, Plaque, Food, University, Maguire v Sydney Organising Committee for the Olympic Games (2000), Partnership, Hydrofluorocarbon, RWTH Aachen Faculty of Mechanical Engineering, Refrigeration, Research, Scientific Committee on Antarctic Research, Mechanical, Ice, Climate change, International Conference on Mechanical Industrial & Energy Engineering, Pearson, Methodius, Knowledge, Confusion, Heat, NH3, Benchmarking, CO2, Conference, Safety, Industrial gas, Publishing, Heating, ventilation, and air conditioning, Ammonia

GLASGOW, United Kingdom, June 10, 2023 /PRNewswire-PRWeb/ -- Dr. Andy Pearson, Group Managing Director of Star Refrigeration, was recently recognised for his 18 years of contribution to Ammonia and CO2 refrigeration research at the 10th International Conference on Ammonia and CO2 Refrigeration Technologies. Organised by the International Institute of Refrigeration (IIR) and the Faculty of Mechanical Engineering of the University of Ss Cyril & Methodius –Skopje, the conference was held in Ohrid, North Macedonia.

Key Points: 
  • GLASGOW, United Kingdom, June 10, 2023 /PRNewswire-PRWeb/ -- Dr. Andy Pearson, Group Managing Director of Star Refrigeration, was recently recognised for his 18 years of contribution to Ammonia and CO2 refrigeration research at the 10th International Conference on Ammonia and CO2 Refrigeration Technologies.
  • The biannual specialist conference unites the world's preeminent scientists and industry leaders to promote knowledge exchange and foster innovation in ammonia and CO2 refrigeration technology.
  • Since its inception in 2005, the conference's objective has been to dispel ambiguities and confusion surrounding ammonia and CO2 refrigeration technologies.
  • The IIR International Conference in Ohrid is a pivotal industry event for knowledge exchange on Ammonia and CO2 Refrigeration Technologies.

AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease

Retrieved on: 
Monday, November 21, 2022
Marketing, ADAS, Inflammation, ANSM, Cell, Cognition, ADAS-Cog, Donanemab, Amyotrophic lateral sclerosis, B cell, AMF, Incidence, III, Degenerative disease, Patient, Cholinesterase, Veterinary medicine, Medicine, MMSE, ALS, Alzheimer's disease, Organic, Mini–Mental State Examination, Scientific Committee on Antarctic Research, AB, University, AD, Disease, Multiple sclerosis, Research, Science, Memantine, Safety, PKI, Reno 1868 FC, Communication, Euronext Paris, Macrophage, Tyrosine kinase inhibitor, European Medicines Agency, Microglia, Central nervous system, AE, INT, Mast cell, Memory, Survival, Pharmaceutical industry, Dietary supplement, Vaccine, Copper, Neurodegeneration

The primary endpoint of study AB21004 will be to evaluate the effect of masitinib on absolute change from baseline in ADCS-ADL score and in ADAS-Cog-11.

Key Points: 
  • The primary endpoint of study AB21004 will be to evaluate the effect of masitinib on absolute change from baseline in ADCS-ADL score and in ADAS-Cog-11.
  • Furthermore, masitinib is an orally administered tyrosine kinase whereas the aforementioned anti-amyloid antibody drugs are administered via injection.
  • The trial (AB21004) aims to confirm the outcomes observed in the previous masitinib phase 2B/3 study (AB09004) supporting the efficacy and safety of masitinib.
  • Study AB09004 was the first successful phase 2B/3 randomized trial in mild-to-moderate Alzheimers disease of a drug targeting innate immune cells of the neuroimmune system.

AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease

Retrieved on: 
Monday, October 10, 2022
Medicine, Mini–Mental State Examination, Euronext Paris, Scientific Committee on Antarctic Research, Science, INT, ADAS, Lists of diseases, Sorbonne University, AMF, Population, Donanemab, ALS, Company, MMSE, Marketing, Neurology, Veterinary medicine, Incidence, Communication, Central nervous system, Macrophage, B cell, Research, Cell, Mast cell, Memantine, Degenerative disease, Microglia, PKI, Alzheimer's disease, Ageing, AD, Survival, Inflammation, Vacuum, Memory, Cholinesterase, Disease, Multiple sclerosis, ADAS-Cog, Cognition, Patient, Amyotrophic lateral sclerosis, III, MD, Safety, AE, AB, Tyrosine kinase inhibitor, Pharmaceutical industry, Medical imaging, Vaccine, Dietary supplement, Copper, Neurodegeneration

The objective of study AB21004 is to confirm treatment effect with masitinib 4.5 mg/kg/day as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.

Key Points: 
  • The objective of study AB21004 is to confirm treatment effect with masitinib 4.5 mg/kg/day as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.
  • Professor Bruno Dubois, MD, principal investigator of the study and Professor of Neurology at Sorbonne University, France commented, We are very excited to initiate this confirmatory phase III study with masitinib in Alzheimers disease.
  • There is a vacuum of treatment options for patients with mild or moderate Alzheimers disease.
  • The results from first phase 2B/3 study, AB09004, were very encouraging, especially considering this is a difficult to treat patient population.

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Retrieved on: 
Wednesday, August 3, 2022
Biotechnology, Pharmaceutical, General Health, Health, COVID-19, Children, Infectious Diseases, Consumer, NASDAQ, Vaccine, Safety, Foot-and-mouth disease virus, Minor, Department, R, Program, Center, Health Bureau, H5N1, WHO, Scientific Committee on Antarctic Research, Infection, HFMD, Sinovac Biotech, Mumps, III, Scientific Committee on Emerging and Newly Identified Health Risks, Polio, Chickenpox, Hepatitis A, COVID-19, CoronaVac, Company, EV71, Carrie Lam as Chief Executive of Hong Kong, Vaccination, Streptococcus, COVID-19 vaccine, Ageing, Zoonosis, Influenza A virus subtype H1N1, Government

The vaccination schedule for this age group follows the same vaccination schedule of older children.

Key Points: 
  • The vaccination schedule for this age group follows the same vaccination schedule of older children.
  • SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
  • Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

WORLD PREVIEW PRESENTATION OF THE "CITTASLOW METROPOLIS" PROJECT

Retrieved on: 
Thursday, June 9, 2022
Rur, Assembly, Palazzo del Capitano del Popolo, Gubbio, Scientific Committee on Antarctic Research, European, Political economy, International relations, City, Travel, COVID-19, International, University, Compliance, Representations, Seoul University, Drug, Management, Asolo, Cittaslow

ORVIETO, Italy, June 9, 2022 /PRNewswire/ -- 

Key Points: 
  • How to transfer the "good living" of the Cittaslow to the metropolitan districts of large cities.
  • Cittaslow means planning and realizing a positive future and community promoting peace and everyday sustainable activities.
  • The Mayors of the Cittaslow International are starting to travel to Orvieto.
  • The President of Cittaslow, Mauro Migliorini, Mayor of Asolo, will open the assembly on Friday 10th June with a round table dedicated to the Cittaslow Metropolis Project.

WORLD PREVIEW PRESENTATION OF THE "CITTASLOW METROPOLIS" PROJECT

Retrieved on: 
Thursday, June 9, 2022
Rur, Assembly, Palazzo del Capitano del Popolo, Gubbio, Scientific Committee on Antarctic Research, European, Political economy, International relations, City, Travel, COVID-19, International, University, Compliance, Representations, Seoul University, Drug, Management, Asolo, Cittaslow

ORVIETO, Italy, June 9, 2022 /PRNewswire/ -- 

Key Points: 
  • How to transfer the "good living" of the Cittaslow to the metropolitan districts of large cities.
  • Cittaslow means planning and realizing a positive future and community promoting peace and everyday sustainable activities.
  • The Mayors of the Cittaslow International are starting to travel to Orvieto.
  • The President of Cittaslow, Mauro Migliorini, Mayor of Asolo, will open the assembly on Friday 10th June with a round table dedicated to the Cittaslow Metropolis Project.

Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors

Retrieved on: 
Tuesday, February 22, 2022
Shareholder, Sanofi, Daiichi Sankyo, Scientific Committee on Antarctic Research, Pediatrics, Master, Capgemini, Oncology, Research, Schering-Plough, University College Utrecht, Board, UMC, Sony, Johnson & Johnson, Leadership, General officer, SAN, Doctor of Philosophy, AstraZeneca, Netherlands Cancer Institute, SNY, NKI, NASDAQ, PricewaterhouseCoopers, Center, Groupe Fnac Darty, DNA, ESMO, University, Social responsibility, Annual, Medicine, ASCO, Science, Intention, Management, Pharmaceutical industry, Lead, Director

Sanofis Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors

Key Points: 
  • Sanofis Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors
    Paris, February 22, 2022.
  • Melanie Lee and Carole Piwnica will leave the Board of Directors.
  • Carole Ferrand is currently Chief Financial Officer of the Capgemini Group and Director of Fnac Darty.
  • Then, she served on the Board of Directors of Capgemini for two years (2016-2018) before being appointed to her current position as Group CFO.

AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit

Retrieved on: 
Monday, February 7, 2022
Prevalence, Inflammation, Riluzole, Disorder, Medicine, ALS, Degenerative disease, Muscle, Research, Motor neuron disease, Multiple sclerosis, Cell, Company, Amyotrophic lateral sclerosis, Pengkhianatan G30S/PKI, Marketing, AB, Clinical trial, Person, JAMA Neurology, B cell, Patient, Tyrosine kinase inhibitor, AMF, Euronext Paris, Survival, Neurodegeneration, Safety, Population, Science, Neurology, Death, Lists of diseases, Drug development, Disease, Veterinary medicine, Scientific Committee on Antarctic Research, Amyotrophy, Euronext, Survival analysis, Motor neuron, Pharmaceutical industry, Silviculture, Vaccine, Aluminium

AB Science SA (Euronext - FR0010557264 - AB) today announced that Professor Olivier Hermine, President of the Scientific Committee of AB Science, will deliver a presentation on the amyotrophic lateral sclerosis (ALS) masitinib development program to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, at the up-coming ALS Drug Development Summit in Boston, USA (May 24-26, 2022).

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announced that Professor Olivier Hermine, President of the Scientific Committee of AB Science, will deliver a presentation on the amyotrophic lateral sclerosis (ALS) masitinib development program to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, at the up-coming ALS Drug Development Summit in Boston, USA (May 24-26, 2022).
  • Additional information on the ALS Drug Development Summit can be found at the meeting website: https://www.als-drug-development.com/.
  • The development of masitinib in ALS is also supported by a well-demonstrated mechanism of action using a relevant model.
  • To date, masitinib has demonstrated positive Phase 2B/3 results in three neurodegenerative disorders, namely, amyotrophic lateral sclerosis (ALS) [2,3], Alzheimers disease [4], and progressive forms of multiple sclerosis [5].

AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency

Retrieved on: 
Wednesday, February 2, 2022
Multiple sclerosis, Risk, Immune system, Cell, Pengkhianatan G30S/PKI, Veterinary medicine, Research, MRI, Autoimmune disease, Safety, B cell, Patient, Neurodegeneration, Lists of diseases, Inflammation, ALS, Microglia, Marketing, Company, Immunology, Survival, Tyrosine kinase inhibitor, Medical Products Agency (Sweden), Euronext, AMF, Scientific Committee on Antarctic Research, PPMS, European Medicines Agency, ANSM, Treatment, Neurology, Magnetic resonance imaging, Amyotrophic lateral sclerosis, Central nervous system, Degenerative disease, Macrophage, Euronext Paris, Disease, Medicine, NSPM, AB, European Committee of the Regions, Science, Disability, EDSS, Pharmaceutical industry, Medical imaging, Vaccine, Masitinib

AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the Swedish Medical Products Agency, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS).

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the Swedish Medical Products Agency, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS).
  • To date, masitinib has demonstrated positive Phase 2B/3 results in three neurodegenerative disorders, namely, Alzheimers disease [1], amyotrophic lateral sclerosis (ALS) [2,3], and progressive forms of multiple sclerosis [4].
  • This confirmatory study follows successful completion of a first Phase 2B/3 study (AB07002) in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis.
  • Published 2021 Jul 19. doi:10.1177/17562864211030365
    [4] Vermersch P, Hermine O. Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: results from phase 3 study AB07002.

The 7th Annual Emerald Conference Produced by MJBizScience Returns to San Diego

Retrieved on: 
Thursday, January 27, 2022
Software, Research, General Health, Tobacco, Technology, Agriculture, Natural Resources, Retail, Science, Alternative Medicine, Other Science, Health, Emerald, CEO, Genetics, Doctor of Philosophy, Rights, Industrial & Engineering Chemistry Research, CTO, Research, Technology, Artificial intelligence, University, Durkee, Centre for Scientific Research into Plant Medicine, Therapy, Cannabis, Science, Scientific Committee on Antarctic Research, Loews Coronado Bay Resort Surf Dog Competition, Industry, MRL, PerkinElmer, Pesticide, University of California, Mycotoxin, Imperial Chemical Industries, Commerce, CSO, Roger Hawkins (drummer), Publication, Analysis, SVP, Conference, PLC, Gemstone, Pharmaceutical industry, Management, Video game, Drug, Emulsion, New Ventures

The Emerald Conference, curated by the Emerald Conferences Scientific Committee, returns in person, February 27-March 1, 2022 to the Loews Coronado Bay Resort in San Diego.

Key Points: 
  • The Emerald Conference, curated by the Emerald Conferences Scientific Committee, returns in person, February 27-March 1, 2022 to the Loews Coronado Bay Resort in San Diego.
  • Keynote speaker, Dr. Daniele Piomelli, Distinguished Professor of University of California Irvine will kick-off the conference on Monday, February 28.
  • We are very excited to have Dr. Piomelli join us as the keynote presenter at the upcoming Emerald Conference.
  • MJBiz acquired The Emerald Conference in early 2020 from founding sponsor Emerald Scientific.